# Exploratory IND Template for VPT-101 Micro-dose Study

## FDA Guidance Compliance
This template follows FDA guidance for Exploratory IND studies (14-day review timeline).

## Study Design: Single IV Micro-dose (0.01 mg kg⁻¹)

### Primary Objectives
1. **Vault PK Assessment**: LC-MS/MS quantification of unique peptide tag
2. **Proof-of-Mechanism**: Real-time Raman spectroscopy of serum PET fragments
3. **Safety Profile**: Sub-pharmacologic dose safety evaluation

### Study Population
- **Sample Size**: 6 healthy volunteers
- **Age Range**: 18-65 years
- **Health Status**: No known plastic exposure, normal liver/kidney function
- **Exclusion Criteria**: Pregnancy, recent plastic surgery, known PET allergies

### Endpoints

#### Primary Endpoints
- **Vault PK**: Plasma concentration-time curve (0-24h)
- **PET Degradation**: Raman spectroscopy at 0, 2, 4, 8, 12, 24h
- **Safety**: Vital signs, CBC, chemistry panel, urinalysis

#### Secondary Endpoints
- **Biodistribution**: Tissue sampling (optional biopsies)
- **Metabolite Analysis**: LC-MS/MS of degradation products
- **Immune Response**: Cytokine panel, complement activation

### Dosing Protocol
```
Day 1: Baseline measurements
Day 2: Single IV infusion (0.01 mg kg⁻¹ over 30 min)
Days 3-8: Daily monitoring
Day 14: Final safety assessment
```

### Safety Monitoring
- **Real-time**: Continuous ECG, pulse oximetry during infusion
- **Daily**: Vital signs, adverse event assessment
- **Weekly**: Laboratory safety panels
- **Emergency**: Immediate discontinuation protocol

### Statistical Analysis
- **Sample Size**: 6 subjects (pilot study)
- **Primary Analysis**: Descriptive statistics
- **Safety Analysis**: Incidence of adverse events
- **PK Analysis**: Non-compartmental modeling

### Regulatory Timeline
- **IND Submission**: Day 0
- **FDA Review**: 14 days (Exploratory IND)
- **Study Start**: Day 15 (if approved)
- **Interim Report**: Day 30
- **Final Report**: Day 60

## Required Documentation

### Pre-IND Meeting Request
- Briefing document (5 pages max)
- Study protocol summary
- Toxicology data summary
- Manufacturing information

### IND Application Components
1. **Form FDA 1571**
2. **Form FDA 1572** (Investigator's Statement)
3. **Protocol**: Complete study protocol
4. **Chemistry, Manufacturing, and Controls (CMC)**
5. **Nonclinical Pharmacology/Toxicology**
6. **Previous Human Experience**
7. **Additional Information**

### CMC Requirements
- **Drug Substance**: Vault nanoparticle characterization
- **Drug Product**: Formulation, stability, sterility
- **Manufacturing**: GMP-compliant production
- **Quality Control**: Release specifications

### Toxicology Package
- **Acute Toxicity**: Single-dose studies (2 species)
- **Repeat-Dose**: 7-day studies (1 species)
- **Genotoxicity**: Ames test, micronucleus
- **Safety Pharmacology**: Cardiovascular, respiratory, CNS

## Risk Mitigation

### Known Risks
- **Allergic Reaction**: Pre-treatment with antihistamines
- **Infusion Reaction**: Slow infusion rate, monitoring
- **Off-target Effects**: Negative control vaults included

### Unknown Risks
- **Long-term Effects**: Limited by micro-dose design
- **Immune Response**: Monitoring for cytokine release
- **Biodistribution**: Tissue sampling for analysis

## Success Criteria
- **Safety**: No serious adverse events
- **PK**: Detectable vault levels in plasma
- **Mechanism**: PET degradation confirmed by Raman
- **Regulatory**: FDA approval for full-dose study

## Next Steps
1. **Pre-IND Meeting**: Schedule with FDA
2. **Manufacturing**: Scale-up GMP production
3. **Toxicology**: Complete required studies
4. **IND Submission**: Submit complete package
5. **Study Initiation**: Begin recruitment

## Contact Information
- **Sponsor**: VPT-101 Consortium
- **Principal Investigator**: [To be determined]
- **Regulatory Affairs**: screball7605@aol.com
- **FDA Contact**: [Division of Clinical Trial Design and Analysis]

---

*This template is provided under CC0 1.0 Universal license. Modify as needed for your specific study requirements.* 